Английская Википедия:Endocyte
Шаблон:Short description Шаблон:Infobox company
Endocyte (NASDAQ: ECYT) is a biopharmaceutical company established in 1996 and headquartered in West Lafayette, Indiana,[1] a resident of the Purdue Research Park.[2] In 2011 the company completed successfully an initial public offering (IPO).[3] Шаблон:As of, the company had 93 employees.[1] The original president and CEO, Ron Ellis,[1] was succeeded by Mike Sherman, who held a CFO position at the company before this change in June 2016. In 2018 the company was acquired by Novartis.[4]
Endocyte is advancing the first technology platform for the creation of small molecule drug conjugates (a.k.a. SMDCs), which consist of a small molecule linked to a potent drug, and is developing a pipeline of SMDCs together with non-invasive companion imaging agents for cancer, inflammatory diseases and kidney disease (autosomal-dominant polycystic kidney disease/ADPKDor PKD).[1][5] Endocyte’s lead drug candidate is vintafolide, an investigational targeted cancer therapeutic in late-stage development. In 2012 marketing rights were acquired by Merck for $120 million in an upfront payment and up to $880 million in milestone payments.[6] Vintafolide is a small molecule drug conjugate consisting of a small molecule targeting the folate receptor, which is expressed on many cancers, such as ovarian cancer, and a potent chemotherapy drug, a derivative of vinblastine.[1] Endocyte retained rights to the development and commercialization of etarfolatide.[6]
Endocyte’s other preclinical drug candidates also target the folate receptor as well as prostate-specific membrane antigen (PSMA) receptors.[1] The company was formed based on technology developed by Philip Low (the company's CSO), and Christopher Leamon, PhD, the company’s VP of research. This technology is a folic acid-based drug delivery system,[1] referred to now as folate targeting.[7] The company is also developing SMDCs with varying drug payloads as well as different ligands for other molecular targets, such as prostate-specific membrane antigen (PSMA) and has also developed, with Bristol-Myers Squibb, an epothilone-folic acid conjugate (BMS-753493), described at a 2008 conference.[8]
In mid-October 2018, Novartis announced it would acquire Endocyte Inc for $2.1 billion ($24 per share) merging it with a newly created subsidiary.[9][10] Endocyte will bolster Novartis' offering in its radiopharmaceuticals business, with Endocyte's first in class candidate 177Lu-PSMA-617 being targeted against metastatic castration-resistant prostate cancer.[11]
References
External links
Шаблон:Finance links historical
- Английская Википедия
- 1996 establishments in Indiana
- Pharmaceutical companies established in 1996
- West Lafayette, Indiana
- Pharmaceutical companies of the United States
- Health care companies based in Indiana
- Companies formerly listed on the Nasdaq
- 2011 initial public offerings
- 2018 mergers and acquisitions
- American subsidiaries of foreign companies
- Novartis
- Страницы, где используется шаблон "Навигационная таблица/Телепорт"
- Страницы с телепортом
- Википедия
- Статья из Википедии
- Статья из Английской Википедии
